Table 3.
Adverse events associated with LEN (n = 177).
| Adverse Event | Any n (%) | Grade 1 n (%) | Grade 2 n (%) | Grade 3 ≥, n (%) |
|---|---|---|---|---|
| Hypertension | 94 (53.1%) | 12 (6.8%) | 56 (31.6%) | 26 (14.7%) |
| Appetite loss | 93 (52.5%) | 40 (22.6%) | 43 (24.2%) | 10 (5.6%) |
| Fatigue | 90 (50.8%) | 24 (13.6%) | 46 (25.9%) | 20 (11.3%) |
| Hypothyroidism | 86 (48.6%) | 28 (15.8%) | 58 (31.0%) | 0 (0% |
| Proteinuria | 67 (37.9%) | 27 (15.6%) | 18 (10.2%) | 22 (12.4%) |
| HFSR | 50 (28.2%) | 22 (12.7%) | 17 (9.6%) | 11 (6.2%) |
| Diarrhea | 34 (19.2%) | 11 (6.2%) | 11 (6.2%) | 12 (6.8%) |
| Liver disorder | 49 (27.7%) | 39 (22.0%) | 6 (3.3%) | 4 (2.3%) |
| Hoarseness | 45 (25.4%) | 42 (23.7%) | 3 (1.7%) | 0 (0%) |
| Thrombocytopenia | 34 (19.2%) | 4 (2.3%) | 21 (11.9%) | 9 (5.0%) |
| Hepatic encephalopathy | 18 (10.1%) | 2 (1.1%) | 15 (8.4%) | 1 (0.5%) |
| Ascites | 7 (3.9%) | 5 (2.8%) | 2(1.1%) | 0 (0%) |
| Drug-induced pneumoniae | 3 (1.7%) | 0 (%) | 3 (1.7%) | 0.0 (0) |
LEN, lenvatinib; HFSR, hand-foot-skin-reaction.